Nonsteroidal management of canine pruritus: chlorpheniramine and a fatty acid supplement (DVM Derm Caps) in combination, and the fatty acid supplement at twice the manufacturer's recommended dosage.
Forty-three dogs having pruritus associated with atopy, flea bite hypersensitivity, and idiopathy were randomly assigned to 1 of 2 treatment protocols. Twenty-three dogs received chlorpheniramine in combination with a fatty acid supplement (DVM Derm Caps). Twenty dogs received the fatty acid supplement at twice the manufacturer's recommended dosage. All 43 dogs were known to be unresponsive to chlorpheniramine and the manufacturer's recommended dosage of the fatty acid supplement when either drug was used alone. Pruritus was satisfactorily controlled in 34.8% of the dogs in the chlorpheniramine--DVM Derm Caps protocol. No dog in the double DVM Derm Caps protocol showed a beneficial response. Side effects were uncommon and mild with either protocol.
Department of Clinical Sciences, New York State College of Veterinary Medicine, Cornell University, Ithaca 14853.
D W
DW
Scott
W H
WH
Miller
D000818:Animals; D002744:Chlorpheniramine / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000209:etiology; D004285:Dogs; D005227:Fatty Acids / Q000627:therapeutic use*; D005260:Female; D006967:Hypersensitivity / Q000150:complications / Q000662:veterinary*; D007428:Intradermal Tests / Q000662:veterinary; D008297:Male; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*
D005227:Fatty Acids; D002744:Chlorpheniramine